Mirabegron (** Myrbetriq (primary brand name), Generic mirabegron **)
Other Medications
Description
Mirabegron is not approved for use in colorectal cancer and has no known clinical application in oncology. It is primarily used to treat overactive bladder symptoms such as urgency, frequency, and urge incontinence.
Mechanism of Action
Mirabegron is a selective ?3-adrenoceptor agonist that increases bladder capacity and reduces urgency by relaxing the detrusor muscle.
Side Effects
Hypertension; Urinary tract infection; Headache
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT06534762
Phase 2
Recruiting
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
China
Quick Info
| Brand Name | ** Myrbetriq (primary brand name), Generic mirabegron ** |
| Category | Other Medications |
 EMA Status | EMA Approved |
 Spain Access | Hospital use other indication |
| Clinical Trials | 1 |
Related Medications
Uracil
Other Medications
787 trials
Leucovorin
Other Medications
648 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.